Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors)

Human Pathology

Volumn 40, Issue 12, 2009, Pages 1706-1714

  Schmitz, Klaus Jürgen ^a   Lang, Hauke ^c   Kaiser, Gernot ^a   Wohlschlaeger, Jeremias ^a   Sotiropoulos, Georgios Charalambos ^c   Baba, Hideo Andreas ^a   Jasani, Bharat ^b   Schmid, Kurt Werner ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cholangiocarcinoma; Immunohistochemistry; Metallothionein

Indexed keywords

METALLOTHIONEIN;

ADULT; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KLATSKIN TUMOR; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HEPATIC DUCT, COMMON; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; KLATSKIN'S TUMOR; MALE; METALLOTHIONEIN; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 70449084872     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.01.026     Document Type: Article

References (28)

1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001) 1353-1357
2. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinct clinical and pathological features. Am J Med 38 (1965) 241-256
3. Coyle P., Philcox J.C., Carey L.C., and Rofe A.M. Metallothionein: the multipurpose protein. Cell Mol Life Sci 59 (2002) 627-647
4. Kagi J.H. Overview of metallothionein. Methods Enzymol 205 (1991) 613-626
5. Sato M., and Bremner I. Oxygen free radicals and metallothionein. Free Radic Biol Med 14 (1993) 325-337
6. Skroch P., Buchman C., and Karin M. Regulation of human and yeast metallothionein gene transcription by heavy metal ions. Prog Clin Biol Res 380 (1993) 113-128
7. Dalton T., Paria B.C., Fernando L.P., et al. Activation of the chicken metallothionein promoter by metals and oxidative stress in cultured cells and transgenic mice. Comp Biochem Physiol B Biochem Mol Biol 116 (1997) 75-86
8. Murphy B.J., Kimura T., Sato B.G., Shi Y., and Andrews G.K. Metallothionein induction by hypoxia involves cooperative interactions between metal-responsive transcription factor-1 and hypoxia-inducible transcription factor-1alpha. Mol Cancer Res 6 (2008) 483-490
9. Chubatsu L.S., and Meneghini R. Metallothionein protects DNA from oxidative damage. Biochem J 291 Pt 1 (1993) 193-198
10. Murphy B.J., Laderoute K.R., Chin R.J., and Sutherland R.M. Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells. Cancer Res 54 (1994) 5808-5810
11. Jasani B., and Schmid K.W. Significance of metallothionein overexpression in human tumours. Histopathology 31 (1997) 211-214
12. Theodoropoulos G.E., Lazaris A.C., Theodoropoulos V.E., et al. Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer. Int J Colorectal Dis 21 (2006) 248-257
13. Sobin L.H., and Wittekind C. International Union against Cancer. TNM Classification of Malignant Tumours. 6th ed (2002), Wiley-Liss, New-York
14. Schmitz K.J., Lang H., Frey U.H., et al. GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 9 (2007) 159-165
15. Schmitz K.J., Lang H., Wohlschlaeger J., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch 450 (2007) 135-141
16. Lang H., Sotiropoulos G.C., Fruhauf N.R., et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 241 (2005) 134-143
17. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 33-42
18. Endo I., Gonen M., Yopp A.C., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248 (2008) 84-96
19. Cherian M.G., Jayasurya A., and Bay B.H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533 (2003) 201-209
20. Shimoda R., Achanzar W.E., Qu W., et al. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 73 (2003) 294-300
21. Theocharis S.E., Margeli A.P., Klijanienko J.T., and Kouraklis G.P. Metallothionein expression in human neoplasia. Histopathology 45 (2004) 103-118
22. Datta J., Majumder S., Kutay H., et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 67 (2007) 2736-2746
23. Shukla V.K., Aryya N.C., Pitale A., et al. Metallothionein expression in carcinoma of the gallbladder. Histopathology 33 (1998) 154-157
24. Cherian M.G., and Apostolova M.D. Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol (Noisy -le-grand) 46 (2000) 347-356
25. Ogra Y., and Suzuki K.T. Nuclear trafficking of metallothionein: possible mechanisms and current knowledge. Cell Mol Biol (Noisy -le-grand) 46 (2000) 357-365
26. Moffatt P., and Denizeau F. Metallothionein in physiological and physiopathological processes. Drug Metab Rev 29 (1997) 261-307
27. Jarnagin W.R., Bowne W., Klimstra D.S., et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 241 (2005) 703-712
28. Chun J.H., Kim H.K., Kim E., et al. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res 64 (2004) 4703-4706